risankizumab-rzaa

risankizumab-rzaa (SKYRIZI) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

SKYRIZI is a marketed brand name for risankizumab-rzaa. Check FDA Drugs@FDA for the current US label holder and prescribing information.

risankizumab-rzaa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.